SCHEMBL314460

SCHEMBL314460

COc1ccc(-c2nnc3n2-c2cc(OC)ccc2NCC3C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
HPGD P15428 6/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP3A4 P08684 1/20 0.41
OXTR P30559 2/20 0.38
LMNA P02545 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GLA P06280 1/20 0.38
AVPR2 P30518 1/20 0.37
AVPR1A P37288 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 2/20 0.35
CUL4A Q13619 1/20 0.35
PDE4A P27815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314462 1.00 ALDH1A1 (0.41) ALDH1A1HPGDCYP2C9CYP2C19CYP3A4
SCHEMBL314461 1.00 ALDH1A1 (0.41) ALDH1A1HPGDCYP2C9CYP2C19CYP3A4
SCHEMBL314717 0.93 HPGD (0.44) ALDH1A1HPGDCYP2C9CYP2C19CYP3A4
SCHEMBL314715 0.93 HPGD (0.44) ALDH1A1HPGDCYP2C9CYP2C19CYP3A4
SCHEMBL314716 0.93 HPGD (0.44) ALDH1A1HPGDCYP2C9CYP2C19CYP3A4
SCHEMBL313663 0.88 OXTR (0.43) ALDH1A1HPGDOXTRLMNAHSD17B10
SCHEMBL313665 0.88 OXTR (0.43) ALDH1A1HPGDOXTRLMNAHSD17B10
SCHEMBL313664 0.88 OXTR (0.43) ALDH1A1HPGDOXTRLMNAHSD17B10
SCHEMBL315204 0.85 HTT (0.37) CYP3A4TSHRMAPTKMT2ASMN1; SMN2
SCHEMBL315205 0.85 HTT (0.37) CYP3A4TSHRMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 ALDH1A1 2295/4885HPGD 2258/4885CYP2C9 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.